Income Statement Balance Sheet Cash Flow Statement
Annual Financials for ACADIA Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 6.4M 42.14M 2.07M 4.91M 1.15M
Cost of Goods Sold (COGS) incl. D&A - 607,000 - - -
COGS excluding D&A - 0 - - -
Depreciation & Amortization Expense 1.11M 607,000 285,000 109,000 79,000
Depreciation 1.11M 607,000 285,000 109,000 -
Amortization of Intangibles 0 0 0 0 -
Gross Income - 41.53M - - -
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 49.47M 26.43M 23.47M 25.68M 39.36M
Research & Development 40.68M 19.98M 17.31M 18.79M 26.72M
Other SG&A 8.79M 6.45M 6.16M 6.89M 12.64M
Other Operating Expense 0 0 0 0 0
Unusual Expense 1.29M 0 1.16M 0 0
EBIT after Unusual Expense (1.29M) 0 (1.16M) 0 0
Non Operating Income/Expense 0 0 0 0 0
Non-Operating Interest Income 409,000 82,000 87,000 37,000 349,000
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 86,000 37,000 - 0 0
Gross Interest Expense 86,000 37,000 - 0 0
Interest Capitalized 0 0 0 0 0
Pretax Income (45.15M) 15.14M (22.77M) (20.85M) (37.95M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (45.15M) 15.14M (22.77M) (20.85M) (37.95M)
Minority Interest Expense 0 0 0 0 0
Net Income (45.15M) 15.14M (22.77M) (20.85M) (37.95M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (45.15M) 15.14M (22.77M) (20.85M) (37.95M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (45.15M) 15.14M (22.77M) (20.85M) (37.95M)
EPS (Basic) (1.20) 0.39 (0.44) (0.38) (0.44)
Basic Shares Outstanding 37.48M 38.59M 52.18M 55.12M 85.72M
EPS (Diluted) (1.20) 0.39 (0.44) (0.38) (0.44)
Diluted Shares Outstanding 37.48M 38.72M 52.18M 55.12M 85.72M
EBITDA (43.07M) 15.7M (21.41M) (20.78M) (38.22M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.